Novo Nordisk’s Stock Soars After Dropping Metsera Acquisition Bid

Shares of Novo Nordisk (NVO) surged over 4% in pre-market trading on Monday, November 10, 2025, reaching $46.18 after closing at $45.68 the previous session. The jump came as the Danish pharmaceutical giant announced its withdrawal from the acquisition race for obesity drug developer Metsera Inc., effectively ending a fierce bidding war estimated to be worth $10 billion. This strategic retreat clears the path for Pfizer to complete its purchase of Metsera and allows Novo Nordisk to refocus on its core pipeline and key priorities.